This open, clinical study describes the use of lamotrigine in 200 adults and children with drug resistant epilepsy. Lamotrigine was used largely as add-on therapy and outcome was assessed by the patients, parents and carers and the physician in terms of reduction of seizure frequency, drug side-effects and improvement inquality of life. Of the 200 patients, 70 (35%) were rendered seizure free. Lamotrigine was especially helpful in resistant primary generalized epilepsy, complex partial seizures, mixed seizures subsequent to brain damage, Lennox-Gastaut syndrome and in complex partial seizures which secondarily generalized. Fifty-three patients ceased lamotrigine; 30 due to lack of effect, and 13 due to side-effects. Lamotrigine is a very useful antiepileptic medication of a 'broad spectrum' nature being effective in primary generalized epilepsy and partial seizures as add-on therapy. The side-effect profile is good with most side-effects being avoidable.
Introduction
Initial experience with lamotrigine (LTG) has confirmed its anticonvulsant effect14. In the more recent past, it has become apparent that LTG is useful in primary generalized epilepsf-' the Lennox-Gastaut
Syndromes-" and in childhood epilepsyg~11-13. The present report describes the use of lamotrigine in 200 patients, adults and children with epilepsy. It describes the use of LTG in a variety of seizure types paying particular attention to seizure control, drug side-effects, quality of life and the withdrawal of existing antiepileptic drugs (AEDs). It is an open, uncontrolled study documenting clinical experience.
PATIENTS AND METHODS
This report is based on observations from 200 patients who had taken LTG for at least six months, either continuing with the drug or having ceased it due to side-effects or a lack of effect. A lack of effect was defined as an absence of improvement in seizure control over four to six months.
Because of the known interaction between LTG and sodium valproate (VPA), with the latter inhibiting the metabolism of the former, increasing its half life and blood levelsi4,", LTG was introduced slowly. In the first 30 patients studied, LTG was commenced at a dose of 25 mg every other day, increasing the dose every two weeks. Due to the occurrence of a rash in a number of these patients, the introductory dosage schedule was thereafter slowed down. In subsequent patients commenced on the drug, a schedule slower than that recommended by the manufacturers was employed, commencing with a dose of 12.5 mg every third day in patients also taking sodium valproate. The dose was increased every two weeks to 12.5 mg every second day, 12.5 mg twice daily, 12.5 mg mane and 25 mg nocte, 25 mg twice daily, 25 mg mane and 60mg nocte, 50 mg b.d., 50 mg mane and 100 mg nocte, 100 mg twice daily and so on.
Seizure control was assessed against baseline seizure frequency for the preceding three to six months. Of particular interest was a group of 67 patients with cerebral palsy, or who had head injuries leading to epilepsy. This group, a real clinical entity, have been loosely called 'patients with generalized seizures secondary to brain damage'. Seizure control was assessed as:
Seizure eradication-no seizures for over six months. 90% seizure reduction-very sporadic seizures in patients who were previously having numerous (at least daily) seizures. ~75% seizure reduction. ~50% seizure reduction. ~50% seizure reduction. No effect. Deterioration in seizure control.
The patients have been followed up regularly, every one to three months, being asked about drug side-effects at all consultations. In particular, the frequency of rash was sought and signs of carbamazepine (CBZ) intoxication (diplopia, dizziness and ataxia) due to an interaction with LTG. Improvements in quality of life were assessed by patient, parent or carer report and physician observation. Whilst this may appear a bit 'soft', the changes in quality of life which occurred were very obvious.
Antiepileptic drug blood level monitoring was carried out when clinically indicated and LTG levels were not measured as there is little relationship between blood level and seizure control. Pre-existing AEDs were withdrawn, on clinical grounds, where possible.
RESULTS
Two hundred patients were studied with the 147 ongoing patients followed up for 1.75 f 0.8 (0.5-4.1 years) since commencing lamotrigine. The patients were aged 21.8 f 13.1 (l-65) years of age and 109 were female. The duration of LTG therapy was 1.42 f 0.93 (0.01-4.1 years).
A summary of the results is shown in Table 1 . Overall, 70 patients (35%) were rendered seizure N. Buchanan free with the introduction of lamotrigine. This figure includes 13 patients with juvenile myoclinic epilepsy (JME) who were commenced on LTG due to unacceptable sodium valproate side-effects rather than poor seizure control. If the JME patients are excluded from the overall assessment of efficacy, 57 patients (30.8%) became seizure free. Sixty-two (31%) patients reported 83 side-effects including 19 interactions with CBZ, six rashes, 17 episodes of therapeutic LTG intoxication, nine patients with insomnia, 26 miscellaneous side-effects (headache, dizziness, agitation, tremor, etc.) and a deterioration in seizure control in six patients. Three patients, two with a rash and one who developed a stroke-like illness in association with LTG introduction, had the drug re-introduced commencing with 12.5 mg/week, with good effect and no sideeffects. Fifty-three patients ceased LTG, 30 due to a lack of effect, 13 due to side-effects, 4 due to both, 4 showed some effect but side-effects supervened, 1 patient had pseudo-epileptic seizures and 1 patient took herself off all treatment. The 147 ongoing patients were taking 250 other AEDs of which, after introduction of LTG, 127 AEDs were able to be withdrawn and 47 reduced ( Table 2 ). The ongoing patients were taking 5.6 f 2.8 (0.2-15) mg/kg/day of lamotrigine.
Patients with generalized seizures secondary to brain damage Of 67 patients, 17 (25.4%) became seizure free, >90% seizure reduction in 16 patients (24%) In the 55 ongoing patients, there were nine episodes of LTG intoxication, two CBZ/LTG interactions, two instances of tremor, one of insomnia, one rash (successfully rechallenged) and a six-year-old patient taking VPA and NZP developed profound athetosis with LTG 25 mg/day and total seizure control; this sideeffect receded with a dose of 12.5 mg every third day producing >50% seizure control.
Turning to quality of life, 45 of the 67 patients (67%) showed a marked improvement in alertness, cognition and quality of life. As many of these patients are severely disabled, this has to be seen in context. The improvements included increased awareness, a marked reduction in drooling, laughing, smiling, reaching out to people, responding much better to conversation and generally being a more active member of the family. Many of the patients slept less and several parents reported a change in sleep pattern with the patients remaining awake later in the evenings.
Twelve patients ceased LTG, nine due to a lack of effect. One patient showed as increase in seizure frequency, another patient, despite a >50% improvement in seizure control, developed profound agitation and was pulling his hair out when taking VPA, CBZ and LTG 2.5 mg/kg/day. Symptoms receded on withdrawing LTG. The final patient, a 25-yearold man taking VPA, CBZ and CLB, after taking 4 doses of 25 mg LTG daily, developed a stroke-like illness which lasted three days, unassociated with any seizures. Lamotrigine was ceased and the symptoms resolved totally. A cerebral CT scan was normal. LTG has been successfully re-introduced in this patient.
Complex partial seizures
Of the 62 patients, 38 exhibited secondary generalization.
Sixteen patients (26%) became seizure free, nine showed a ~90% improvement in seizure control, eight >75%, one >50%, one ~50% and 25 patients ceased lamotrigine.
One patient who was seizure free, but drug intoxicated with PHT and CZP, had lamotrigine introduced and CZP withdrawn. She is now alert and back at part-time studies, but has occasional complex partial seizures. In the 35 ongoing patients, there were five episodes of CBZ/LTG intoxication, resolved by lowering the CBZ dose and three patients developed LTG intoxication due to excessive dosage. Eleven patients (19%) showed a marked improvement in alertness and behaviour.
Twenty-seven patients ceased LTG, 16 due to a lack of effect, one due to CBZ intoxication, three developed a rash, four showed increased seizure frequency, one developed severe headaches, one patient became dizzy and agitated and one patient decided she did not have epilepsy and ceased all her medications with unfortunate effect. All symptoms resolved with LTG withdrawal, except one patient with a vesicular rash which was not felt to be LTG related.
Primary generalized epilepsy
Juvenile myoclonic epilepsy There were 15 patients all of whom were free of major seizures, including the two patients not on lamotrigine.
Eleven of these 13 LTG patients have no GTCS and no myoclonus, whilst two have no GTCS but some morning myoclonus when sleep deprived. Two patients developed transient side-effects; lip and tongue swelling and in another patient, LTG intoxication. One patient ceased lamotrigine due to insomnia and being on a perpetual 'high' and the other patient, who takes CBZ, CLB and sulthiame, developed headaches with LTG and abandoned it. As previously mentioned, these patients were commenced on LTG largely because of VPA sideeffects:-weight gain, hair loss and fluid retention. Sodium valproate has so far been successfully withdrawn in four patients, of whom three have lost 7 of 11 kg weight gain, 5 of 22 kg and 4 of 7 kg weight gain. In the latter patient, hair loss has also ceased. In one other patient, violent dreams associated with VPA have ceased.
Absences f generalized tonic-clonic seizures (GTCS)
Of the 26 patients, 18 became seizure free, 1 showed a >90% seizure reduction, three >75%, one ~50% and in the final patient GTCS are controlled and absences ~75% so. In terms of side-effects, one patient was therapeutically LTG intoxicated three times and one patient overdosed herself. One patient already on VPA did not respond to LTG; telemetry showed the episodes to be non-epileptic. Finally, one patient ceased LTG due to double vision, headache and dizziness whilst also taking VPA.
Tonic seizures (documented by video-EEG monitoring)
Of the seven patients, one is seizure free, three have >90%, and one patient has a >50% reduction in seizures. Two patients have ceased LTG treatment. In the five ongoing patients, one patient had a CBZ/LTG interaction, one developed LTG intoxication and all the patients have shown a marked improvement in quality of life. Two patients ceased LTG due to a lack of effect with one of these patients developing CBZ intoxication.
Lennox-Gastaut syndrome
There were 14 patients of whom three (21%) are now seizure free, two have shown a >90% reduction in seizures, one >75%, >50% in two patients, <50% in another patient and four have ceased treatment with LTG. In the ongoing nine patients, there were two episodes of CBZ intoxication, one of LTG intoxication and one patient had a rash .(successfully rechallenged). Seven of the nine patients have shown a marked improvement in alertness, motor skills and conversation. Five patients have ceased LTG treatment, four due to a lack of effect and one, lack of effect with marked drowsiness.
Lamotrigine has been used in nine more patients. Four had simple partial seizures (SPS). A six-year-old girl with SPS, previously taking CBZ and CBL, is now off both drugs and seizure free on LTG 15 mg/kg/day. A nine-year-old girl has shown a >90% reduction in seizures with the addition of LTG to CBZ. Two other patients with SPS did not respond to lamotrigine and it has been withdrawn. Five other patients with a variety of forms of epilepsy have been tried on lamotrigine.
The first is a 47-year-old man with reading epilepsy of 10 years duration taking VPA and CZP. When taking 6.2 mg/kg/day LTG there was a 90% reduction in seizures and taking 6.2 mg/kg/day LTG there was a 90% reduction in seizures and CZP was withdrawn. He subsequently developed an 'autoimmune meningoencephalitis' and lest it be drug related, LTG was withdrawn, with a deterioration in seizure control. An eight-year-old boy with ESES has shown behavioural improvement, but no EEG amelioration, with LTG 13 mg/kg/day. In the case of a five-year-old boy with Landau-Kleffner syndrome, his absences have almost ceased and his speech and behaviour are much improved with LTG 2.5 mg/kg/day. A seven-year-old girl with Angelman's Syndrome is now seizure free and much more alert taking VPA plus LTG 5 mg/kg/day.
Finally, a six-year-old girl with Batten's Disease showed an initial good response to LTG (2 mg/kg/day) in addition to VPA and CZP. This has been lost as her disease has progressed.
DISCUSSION
Lamotrigine has been shown to be effective in both partial16-19 and generalized seizures20-u. The present report looks at the use of LTG as add-on therapy in clinical practice in a substantial number of patients presenting with treatment resistant seizures (excluding the JME patients). It showed that 30.8% became seizure free with the addition of lamotrigine.
This was especially the case in those with absences f tonic-clonic seizures (69%), CPS (33%), brain damage with resultant generalized seizures (25%), LennoxGastaut syndrome (21%) and a similar figure for CPS with secondary generalization.
This data supports the existing evidence that LTG is of value in treatment resistant primary generalized epilepsy including juvenile myoclonic epilep#*=.
In this present study where LTG was used in JME because of VPA side-effects, it has been possible to withdraw VPA in four patients and reduce the dose in all the others. The original side-effects have either been abolished or minimized.
Lamotrigine was helpful in two other groups of patients where treatment is often unsatisfactory; Lennox-Gastaut syndrome and those with brain damage and resultant generalized, often mixed, seizures. Three patients (21%) with LGS became seizure free with 9/14 patients showing benefit in terms of seizure control and quality of life. These observations confirm growing evidence of the usefulness of lamotrigine in LGS'0"c28. The other group of patients with encouraging results was that composed of individuals with brain damage and mixed seizures. Some of these patient's have been described in detail elsewhere29 and thus will be discussed only briefly. With the addition of lamotrigine, 25% became seizure free and a further 40% exhibited a >75%->90% reduction in seizures. As importantly for the patient and their family, 67% showed an improvement in quality of life. When an additional AED is introduced with an improvement in seizure control, it is usual to try and withdraw some of the pre-existing medications. In the present study it was possible to withdraw 51% of the previous AEDs in the 147 ongoing patients especially CBZ, CLB, VGB and CZP. Sodium valproate could frequently be reduced in dosage, but withdrawal was more difficult and not infrequently associated with seizure recurrence. This suggests the possibility of synergism between these two AEDs as discussed elsewhere22*u.
One of the important benefits of open studies is the accurate definition of side-effects as experienced in clinical practice as opposed to clinical trials. Side-effects with LTG can be divided into four groups, three of which are avoidable. Firstly, the interaction with CBZ occurred in 9.5% of patients. This can be minimized by mentioning the interaction to the patient and instructing them to report at once if they develop diplopia, ataxia or dizziness and then cease the CBZ for 24 hours and subsequently reduce the dosage by 25%. The symptoms recede in 48 hours.
The second 213 problem is that of a rash which occurred in 3% of patients, all of whom were taking VPA. These patients were amongst the first 30 patients studied and since using the present slow rate of LTG introduction no further rashes have been seen. Thirdly, there were 17 episodes of LTG intoxication due to excessive dosage increases. These three groups of side-effects should be largely avoidable. Of the remaining miscellaneous sideeffects, the most important were an increase in seizure frequency (3%) and insomnia (4.5%).
Finally, with all AEDs there is a concern about the development of tolerance. This is especially the case with the benzodiazepines, e.g. clobazam with tolerance rates varying from 9-19%302', but also for VGB with figures ranging from 3%32 to 10%33. In the present group of 147 ongoing patients there has to date been no suggestion of tolerance. This will need to be looked for over a more protracted period.
The present report supports the growing view that LTG is a useful 'broad spectrum' AED with a good side-effect profile.
